Clinical trials: Intestinal GVHD
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Graft Versus Host Disease, Postbiotics
Intestinal Microbiome-based Research for the Prevention of Acute GVHD
Hematopoietic stem cell transplantation consists of preconditioning chemotherapy, stem cell infusion, and engraftment of hematopoietic stem cells.
- Conditions
- Graft Versus Host Disease, Postbiotics, Butyrate
- Trial name
- NCT05808985
- Testing
- sodium butyrate
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Soonchunhyang University Hospital
Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD
MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
MaaT013 showed interesting results in steroids and ruxolitinib-resistant aGVHD patients with gut involvement (55% ORR at D28) and 47% and 39% OS at 6 and 12 months respectively (Malard 2020), therefore warrant being tested as…
- Trial name
- ARES (NCT04769895)
- Testing
- MaaT013
- Where
- 50 sites in Austria, Belgium and 4 more
- Volunteers
- 66 people
- Sponsor
- MaaT Pharma
Graft Vs Host Disease
Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation
Twenty-four (2 x 12) patients with intestinal graft versus host disease (GVHD) Grades 2, 3 or 4 will be treated with budesonide 3mg three times daily or placebo for 12 weeks.
- Trial name
- NCT00128739
- Testing
- Budesonide
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Rafa Laboratories
Graft Vs Host Disease, Graft Versus Host Disease
Cellular Stress Reactions During Graft-versus-host Disease
This study has the aim to analyze intestinal expression of cellular stress molecules in patients with intestinal GVHD. Patients with colitis and patients without intestinal inflammation will serve as controls.
- Trial name
- NCT04558788
- Testing
- Immunohistochemistry on intestinal biopsies
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Freiburg
Stem Cell Transplant Complications, Acute Graft-Versus-Host Disease
FMT for Steroid Resistant Gut Acute GVHD
The study aims to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) for the treatment of steroid resistant graft-versus-host-disease (GVHD) of the gut.
- Conditions
- Stem Cell Transplant Complications, Acute Graft-Versus-Host Disease, Fecal Microbiota Transplantation
- Trial name
- NCT04285424
- Testing
- Fecal Microbiota Transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Nutrition Aspect of Cancer, Stem Cell Transplant Complications
Study on Intelligent Nutrition Support Therapy for Hematopoietic Stem Cell Transplantation Recipients
The use of high-dose radiotherapy, chemotherapy and preventive antibiotics in the preconditioning regimen before allogeneic hematopoietic stem cell transplantation can easily lead to damage to the gastrointestinal mucosa…
- Trial name
- NCT05590091
- Testing
- Parenteral nutrition;Enteral nutrition
- Volunteers
- 106 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
Malignant Pain, Non-malignant Pain
To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain
This study is aimed to demonstrate equivalence between combinations of lower strength OXN PR tablets (OXN PR LST) and single higher strength OXN PR tablets (OXN PR HST) taken at the same overall daily dose.
- Trial name
- NCT02321397
- Testing
- Oxycodone, Naloxone
- Where
- Germany
- Volunteers
- 155 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
This pilot phase II trial studies how well giving vorinostat, tacrolimus, and methotrexate works in preventing graft-versus-host disease (GVHD) after stem cell transplant in patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01789255
- Testing
- vorinostat, tacrolimus, cyclosporine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Graft Vs Host Disease
Alterations in Intestinal Microbiota, Metabolites, and Immune Cells in Allo-HSCT
This research project delves into the critical role of gut immunity in the occurrence and progression of acute graft-versus-host disease (aGVHD) post allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- NCT06143501
- Testing
- Blood Sample, Stool Sample, Urine Sample
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
Allogeneic Hematopoietic Stem Cell Transplantation
A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
The purpose of this study is to assess the initial activity, tolerability, safety and to identify a recommended dose and regimen of vedolizumab intravenous (IV) administered for treatment of steroid-refractory acute intestinal…
- Trial name
- NCT02993783
- Testing
- Vedolizumab
- Where
- 15 sites in United States, Belgium and 3 more
- Volunteers
- 17 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Graft Versus Host Disease
Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients
In this study the investigators evaluate the outcomes of six steroid-refractory GVHD patients with gastrointestinal signs of GVHD that were treated with teduglutide.
- Trial name
- NCT04290429
- Testing
- Teduglutide
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- University of Freiburg
Hematopoietic Stem Cell Transplantation, Graft Versus Host Disease
Optimization of Antibiotic Treatment in Hematopoietic Stem Cell Receptors
There are data suggesting that the reduction of the diversity of intestinal microbiota caused by the used treatments in the setting of allogeneic hemopoietic stem cell transplant (ASCT), and specially antibiotics, may be related…
- Trial name
- Optimbioma (NCT03727113)
- Testing
- Optimization cohort, Control cohort
- Where
- 5 sites in Spain
- Volunteers
- 211 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Acute Graft Versus Host Disease in Intestine
Prospective Study of FMT for Acute Intestinal GVHD After Allo-HSCT
Acute intestinal GVHD is the main cause of death after allo-HSCT, and FMT is a new treatment method for this disease. In this prospective study, the investigators will recruit intestinal GVHD patients to demonstrate the efficacy…
- Trial name
- NCT04711967
- Testing
- Fecal Microbiota Transplantation, drug
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Qilu Hospital of Shandong University
Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)
Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD
Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD) is a complication of allogeneic stem cell transplant which is usually treated with steroids.
- Trial name
- NCT04059757
- Testing
- Fecal Microbiota Transplantation (FMT)
- Where
- United States
- Sponsor
- Leland Metheny
Hematopoietic Stem Cells
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
The purpose of this study is to evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in…
- Trial name
- NCT03657160
- Testing
- Vedolizumab
- Where
- 139 sites in United States, Argentina and 25 more
- Volunteers
- 343 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Graft vs Host Disease, Graft Versus Host Disease
Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT
The purpose of this study is to examine the gut bacteria, levels of peripheral blood inflammation markers, and symptoms in patients with and without chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic…
- Conditions
- Graft vs Host Disease, Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation
- Trial name
- NCT02398708
- Testing
- Questionnaires, Blood Sample, Stool Sample
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Florida
Blood Cancer
Development of a Multi-biomarker Panel for Prognostic Stratification and Treatment Response Prediction in Acute Graft Versus Host Disease of the Gut
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a life-saving treatment for many malignant hematologic diseases.
- Trial name
- GUT-PREDICTION (NCT07305090)
- Testing
- Adult and pediatric patients with hematological diseases treated with allogeneic hematopoietic cell transplantation
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hematopoietic Stem Cell Transplantation (HSCT), Acute GVH Disease
Gut Decontamination In Pediatric Allogeneic Hematopoietic
This research study is for participants who are undergoing allogeneic hematopoietic stem cell transplantation (HSCT) and are at risk for developing acute graft-versus-host disease (GVHD).
- Trial name
- NCT02641236
- Testing
- Vancomycin-polymyxin B
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute